Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized withdrawal study of vixotrigine in painful small fiber neuropathy
NL-OMON48621Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vixotrigine in small fiber neuropathy (SFN) and cryptogenic small fiber neuropathy (iSFN), sponsored by Biogen. Primary endpoint: Change in mean average daily pain score from Baseline to Week 12 of the double-blind period. Started Jun 2018; status: active, not recruiting.
02
Drugs
vixotrigine
03
Conditions
small fiber neuropathy (SFN)cryptogenic small fiber neuropathy (iSFN)
Beyond the preview
Go deeper on NL-OMON48621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48621.